1832 Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-116,353
Closed -$16.2M 661
2026
Q1
$16.2M Sell
116,353
-43,459
-27% -$6.09M 0.01% 322
2025
Q4
$19.6M Buy
159,812
+118,979
+291% +$14.5M 0.01% 298
2025
Q3
$4.53M Sell
40,833
-1,467
-3% -$167K ﹤0.01% 383
2025
Q2
$4.69M Buy
+42,300
New +$4.5M ﹤0.01% 376
2024
Q3
Sell
-120
Closed -$8.23K 759
2024
Q2
$8.23K Sell
120
-30,738
-100% -$2.05M ﹤0.01% 786
2024
Q1
$2.26M Sell
30,858
-313
-1% -$24.1K ﹤0.01% 477
2023
Q4
$2.53M Buy
31,171
+7,411
+31% +$577K ﹤0.01% 449
2023
Q3
$1.78M Sell
23,760
-23,105
-49% -$1.78M ﹤0.01% 500
2023
Q2
$3.61M Buy
46,865
+1,047
+2% +$83.5K ﹤0.01% 413
2023
Q1
$3.8M Buy
45,818
+20,612
+82% +$1.71M 0.01% 429
2022
Q4
$2.16M Sell
25,206
-6,961
-22% -$551K ﹤0.01% 511
2022
Q3
$1.98M Sell
32,167
-541
-2% -$34.1K ﹤0.01% 508
2022
Q2
$2.02M Sell
32,708
-8,363
-20% -$518K ﹤0.01% 515
2022
Q1
$2.41M Buy
+41,071
New +$2.63M ﹤0.01% 521
2021
Q4
Sell
-8,933
Closed -$638K 776
2021
Q3
$638K Buy
+8,933
New +$628K ﹤0.01% 524
2021
Q1
Sell
-68,925
Closed -$3.92M 729
2020
Q4
$3.92M Buy
68,925
+25
+0% +$1.51K 0.01% 382
2020
Q3
$4.31M Buy
68,900
+30,800
+81% +$2.14M 0.01% 343
2020
Q2
$2.86M Sell
38,100
-8,000
-17% -$613K 0.01% 366
2020
Q1
$3.52M Buy
46,100
+4,525
+11% +$313K 0.01% 332
2019
Q4
$2.68M Sell
41,575
-1,176
-3% -$76.6K 0.01% 356
2019
Q3
$2.63M Buy
42,751
+102
+0.2% +$6.67K 0.01% 361
2019
Q2
$2.81M Buy
+42,649
New +$2.81M 0.01% 375
2019
Q1
Sell
-39,630
Closed -$2.62M 650
2018
Q4
$2.62M Buy
39,630
+25,596
+182% +$1.79M 0.01% 320
2018
Q3
$1.24M Sell
14,034
-101,845
-88% -$7.69M ﹤0.01% 437
2018
Q2
$8.08M Buy
115,879
+99,238
+596% +$7.01M 0.03% 245
2018
Q1
$1.41M Sell
16,641
-91,605
-85% -$7.28M 0.01% 416
2017
Q4
$7.66M Buy
108,246
+100,067
+1,223% +$7.6M 0.02% 252
2017
Q3
$843K Sell
8,179
-275,108
-97% -$21M ﹤0.01% 439
2017
Q2
$20M Sell
283,287
-67,485
-19% -$4.49M 0.09% 188
2017
Q1
$23.9M Sell
350,772
-807,484
-70% -$56.8M 0.09% 183
2016
Q4
$87.2M Buy
1,158,256
+345,550
+43% +$25.7M 0.15% 151
2016
Q3
$64.3M Sell
812,706
-154,249
-16% -$12.5M 0.24% 102
2016
Q2
$81M Buy
966,955
+875,419
+956% +$77.7M 0.31% 82
2016
Q1
$14M Buy
91,536
+36,524
+66% +$3.29M 0.03% 267
2015
Q4
$5.64M Sell
55,012
-58,324
-51% -$6.07M 0.02% 279
2015
Q3
$11.2M Sell
113,336
-50,353
-31% -$5.59M 0.05% 223
2015
Q2
$19.1M Sell
163,689
-576,759
-78% -$63M 0.06% 221
2015
Q1
$72.8M Sell
740,448
-19,600
-3% -$1.99M 0.27% 94
2014
Q4
$71.6M Buy
760,048
+661,828
+674% +$68.4M 0.22% 105
2014
Q3
$10.5M Sell
98,220
-382,280
-80% -$37.4M 0.03% 291
2014
Q2
$39.9M Sell
480,500
-160,900
-25% -$12.5M 0.13% 170
2014
Q1
$44M Sell
641,400
-451,300
-41% -$35.4M 0.15% 146
2013
Q4
$82.2M Sell
1,092,700
-65,300
-6% -$4.55M 0.32% 81
2013
Q3
$72.7M Sell
1,158,000
-356,500
-24% -$21.3M 0.32% 84
2013
Q2
$77.6M Buy
+1,514,500
New +$78.9M 0.34% 76

Other funds holding GILD

1832 Asset Management's GILD Position: Q2 2026 in Review

1832 Asset Management sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 116,353 shares — an estimated $16.2M sold.

1832 Asset Management first reported a position in GILD in Q2 2013 and held it in 45 quarters. The position peaked at $87.2M in Q4 2016. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • 1832 Asset Management reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • 1832 Asset Management sold 116,353 Gilead Sciences shares in Q2 2026, an estimated $16.2M.
  • 1832 Asset Management first reported a position in Gilead Sciences in Q2 2013 and held it in 45 quarters.
  • 1832 Asset Management's Gilead Sciences position peaked at $87.2M in Q4 2016.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on 1832 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.